Elizabeth Evans - Vaccinex COO Medicine
| VCNX Stock | USD 4.13 0.35 9.26% |
Insider
Elizabeth Evans is COO Medicine of Vaccinex
| Age | 51 |
| Address | 1895 Mount Hope Avenue, Rochester, NY, United States, 14620 |
| Phone | 585 271 2700 |
| Web | https://www.vaccinex.com |
Elizabeth Evans Latest Insider Activity
Tracking and analyzing the buying and selling activities of Elizabeth Evans against Vaccinex stock is an integral part of due diligence when investing in Vaccinex. Elizabeth Evans insider activity provides valuable insight into whether Vaccinex is net buyers or sellers over its current business cycle. Note, Vaccinex insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vaccinex'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Elizabeth Evans over a month ago Acquisition by Elizabeth Evans of 1341 shares of Vaccinex at 8.21 subject to Rule 16b-3 | ||
Elizabeth Evans over six months ago Acquisition by Elizabeth Evans of 1341 shares of Vaccinex at 8.32 subject to Rule 16b-3 |
Vaccinex Management Efficiency
The company has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Vaccinex's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 9.20 in 2024, whereas Return On Tangible Assets are likely to drop (5.86) in 2024. At this time, Vaccinex's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 8.9 M in 2024, whereas Non Currrent Assets Other are likely to drop (1.05) in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nathan Caffo | Candel Therapeutics | 55 | |
| Susan Kahlert | Senti Biosciences | N/A | |
| MD MS | Candel Therapeutics | 53 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Ileen Winick | Candel Therapeutics | N/A | |
| Francesca MD | Candel Therapeutics | 46 | |
| LLM JD | Candel Therapeutics | 63 | |
| Inf MD | Candel Therapeutics | 64 | |
| Wilson Wong | Senti Biosciences | N/A | |
| James Foster | Virax Biolabs Group | 39 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Carrie Cox | Candel Therapeutics | 66 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Jason Amello | Candel Therapeutics | 56 | |
| James Collins | Senti Biosciences | 58 | |
| Seshu Tyagarajan | Candel Therapeutics | 56 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
Management Performance
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 |
Vaccinex Leadership Team
Elected by the shareholders, the Vaccinex's board of directors comprises two types of representatives: Vaccinex inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaccinex. The board's role is to monitor Vaccinex's management team and ensure that shareholders' interests are well served. Vaccinex's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaccinex's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jill CPA, Chief Officer | ||
| Jill Sanchez, Interim Controller | ||
| MBA CFA, Chief Officer | ||
| Ernest Smith, Senior Officer | ||
| Maurice Zauderer, CEO, CoFounder | ||
| Elizabeth Evans, COO Medicine | ||
| John Leonard, Senior Development |
Vaccinex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaccinex a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 | ||||
| Operating Margin | (24.66) % | ||||
| Current Valuation | 8.79 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 9.36 % | ||||
| Shares Owned By Institutions | 49.12 % | ||||
| Number Of Shares Shorted | 112.17 K | ||||
| Price To Book | 7.34 X | ||||
| Price To Sales | 31.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.